TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival.
We conducted the present study to evaluate the frequency and prognostic importance on long-term survival of TP53 mutations and TP53 protein accumulation in a cohort of 178 patients with early-stage ovarian carcinomas. TP53 mutations scored as aberrant temporal temperature gradient gel electrophoresis pattern from all exons were observed in 39.9% of the tumours. Full screening of exons 5-8, followed by sequencing, was successful in 135 cases, and 48 mutations altering the protein were detected in 39 cases (28.9%). TP53 mutations were slightly less common in the Federation of Gynecologists and Obstetricians stage IA than in IB/IC (P=0.05). No significant correlations with histological type, grade of differentiation, DNA ploidy status or age at diagnosis were found. TP53 protein accumulation analysed by immunohistochemistry was found in 32.6% of all tumours, and was a poor predictor of TP53 mutations with 56.4% sensitivity, 77.1% specificity, 50% positive predictive value and 81.3% negative predictive value. Neither TP53 mutations nor TP53 protein accumulation influenced the prognosis significantly in this group of patients.
Wang
Y
Y
Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo N-0310, Norway.
Helland
A
A
Holm
R
R
Skomedal
H
H
Abeler
V M
VM
Danielsen
H E
HE
Tropé
C G
CG
Børresen-Dale
A-L
AL
Kristensen
G B
GB
D000368:Aged; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D005091:Exons; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology*; D011003:Ploidies; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics*
D004273:DNA, Neoplasm; D016159:Tumor Suppressor Protein p53